<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926169</url>
  </required_header>
  <id_info>
    <org_study_id>M16-833</org_study_id>
    <secondary_id>2019-000122-21</secondary_id>
    <nct_id>NCT03926169</nct_id>
  </id_info>
  <brief_title>A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa</brief_title>
  <acronym>DETERMINED 1</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult
      participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two
      treatment periods. In Period A, participants are randomized to receive either risankizumab
      dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or
      placebo during Period A, will receive risankizumab dose B. Participants who received
      risankizumab dose B in Period A will remain on that dose in Period B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">June 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 16</time_frame>
    <description>HiSCR is defined as at least a 50% reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess or draining fistula counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving at least 30% reduction from Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) at Week 8 among participants with Baseline Numerical Rating Scale (NRS) &gt;= 3</measure>
    <time_frame>Baseline (Week 0) to approximately Week 8</time_frame>
    <description>NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving at least 30% reduction from Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) at Week 16 among participants with Baseline Numerical Rating Scale (NRS) &gt;= 3</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experience at least 25% increase in AN counts with a minimum increase of 2 relative to Baseline</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>Percentage of participants who experience at least 25% increase in AN counts with a minimum increase of 2 relative to Baseline is evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>The DLQI is a 10-item validated questionnaire used to assess the impact of HS disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HS-related swelling assessed based on the Hidradenitis Suppurativa Symptom Assessment (HSSA)</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>HSSA is a 9-item patient reported outcome (PRO) questionnaire developed to assess the symptoms of HS on a 0 to 11-point numerical rating scale (NRS), where 0 represents no symptoms and 10 represents extreme symptom experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HS-related odor assessed based on the HSSA</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>HSSA is a 9-item patient reported outcome (PRO) questionnaire developed to assess the symptoms of HS on a 0 to 11-point numerical rating scale (NRS), where 0 represents no symptoms and 10 represents extreme symptom experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HS-related worst drainage assessed based on the HSSA</measure>
    <time_frame>Baseline (Week 0) to approximately Week 16</time_frame>
    <description>HSSA is a 9-item patient reported outcome (PRO) questionnaire developed to assess the symptoms of HS on a 0 to 11-point numerical rating scale (NRS), where 0 represents no symptoms and 10 represents extreme symptom experience.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Risankizumab: Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive risankizumab dose A in treatment period A and placebo followed by risankizumab dose B in treatment period B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab: Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive risankizumab dose B in treatment period A and placebo followed by risankizumab dose B in treatment period B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive Placebo in treatment period A and risankizumab dose B in treatment period B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Risankizumab: Dose A</arm_group_label>
    <arm_group_label>Risankizumab: Dose B</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>SKYRIZI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for risankizumab</intervention_name>
    <description>Placebo for risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Risankizumab: Dose A</arm_group_label>
    <arm_group_label>Risankizumab: Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with moderate to severe Hidradenitis Suppurativa (HS) for at least one
             year prior to baseline visit.

          -  HS lesions present in at least two distinct anatomical areas.

          -  Draining fistula count of &lt;=20 at Baseline visit.

          -  Total abscesses and nodule count (AN count) of &gt;= 5 at Baseline visit.

          -  Participants are required to use a daily antiseptic wash on their HS lesions .

          -  Participant must have a history of inadequate response or intolerance to an adequate
             trial of oral antibiotics for treatment of HS.

        Exclusion Criteria:

          -  Participant has a history of active skin disease other than HS that could interfere
             with the assessment of HS.

          -  Participant has active tuberculosis (TB) or concurrent treatment for latent TB or
             evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immuno
             deficiency virus (HIV) infection.

          -  Participant has prior exposure to anti-interleukin-1 (anti-IL-1) treatment within 3
             months or 5 half-lives, whichever is longer, prior to baseline.

          -  Participant has received prescription topical therapies (including topical
             antibiotics) within 14 days prior to the Baseline visit.

          -  Participant has received systemic non-biologic therapies that can also be used to
             treat HS within 4 weeks prior to the Baseline visit.

          -  Participant has received any systemic (including oral) antibiotic treatment within 4
             weeks prior to the Baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research /ID# 211671</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913-6404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bakersfield Derma &amp; Skin Cance /ID# 211684</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wallace Medical Group, Inc. /ID# 215958</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integrative Skin Science and Research /ID# 212550</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815-4500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis, Dermatology /ID# 211436</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Dermatology Institute /ID# 211786</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320-2130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Connecticut Dermatology /ID# 214479</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416-1745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research /ID# 215203</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328-6141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology /ID# 219096</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center /ID# 212680</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 211794</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology /ID# 212318</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota /ID# 212319</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center /ID# 211979</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC /ID# 211675</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center /ID# 211800</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Res Center PC /ID# 211796</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Ctr /ID# 211659</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital /ID# 211807</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PL /ID# 215202</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research /ID# 215959</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 211799</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology /ID# 212437</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital /ID# 212438</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research /ID# 212432</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Health Institute Inc /ID# 212433</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology /ID# 215548</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 212436</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology /ID# 212434</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research, CA /ID# 212243</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Irina Turchin PC Inc. /ID# 212248</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. S.K. Siddha Medicine Professional Corporation /ID# 219043</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research /ID# 212166</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dre Angelique Gagne-Henley M.D. inc. /ID# 212249</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 7E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Prive d'Antony /ID# 212566</name>
      <address>
        <city>Antony</city>
        <state>Ile-de-France</state>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot /ID# 218408</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice /ID# 212563</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinique Courlancy /ID# 212567</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne, Hopital Nord /ID# 212564</name>
      <address>
        <city>SAINT-ETIENNE Cedex 1</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey - CHU de Toulouse /ID# 213581</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt /ID# 211913</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Ruhr Univ Bochum /ID# 211910</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Dessau /ID# 211914</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Klinik Eppendorf Hamburg /ID# 211912</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital /ID# 211155</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital /ID# 211303</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital /ID# 212214</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital /ID# 211373</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital /ID# 211742</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis /ID# 212536</name>
      <address>
        <city>Bergen op Zoom</city>
        <state>Noord-Brabant</state>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis /ID# 212538</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum /ID# 212535</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante /ID# 212010</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau /ID# 212009</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli /ID# 212015</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves /ID# 212014</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon /ID# 212011</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Uni Virgen de la Victoria /ID# 212013</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises /ID# 211541</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>Risankizumab</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

